StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note published on Tuesday morning. The brokerage issued a sell rating on the stock.
Moleculin Biotech Price Performance
Shares of NASDAQ MBRX opened at $2.47 on Tuesday. The company’s fifty day simple moving average is $2.90 and its 200 day simple moving average is $4.55. Moleculin Biotech has a 12-month low of $2.12 and a 12-month high of $15.75.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($2.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). As a group, sell-side analysts forecast that Moleculin Biotech will post -8.6 EPS for the current fiscal year.
Hedge Funds Weigh In On Moleculin Biotech
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
See Also
- Five stocks we like better than Moleculin Biotech
- Stock Sentiment Analysis: How it Works
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- The Role Economic Reports Play in a Successful Investment Strategy
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- Consumer Staples Stocks, Explained
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.